FFA
CVKD icon

Farther Finance Advisors’s Cadrenal Therapeutics CVKD Stock Holding History

Farther Finance Advisors’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84 Hold
25
– – ﹤0.01% 5808
2026
Q1 		$123 Hold
25
– – ﹤0.01% 5489
2025
Q4 		$170 Hold
25
– – ﹤0.01% 5231
2025
Q3 		$346 Hold
25
– – ﹤0.01% 4621
2025
Q2 		$301 Hold
25
– – ﹤0.01% 4137
2025
Q1 		$437 Hold
25
– – ﹤0.01% 3798
2024
Q4 		$362 Buy
+25
New +$361 ﹤0.01% 3510

Other funds holding CVKD

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GBT
Grove Bank & Trust Miami, Florida $1.01B AUM 26.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

Farther Finance Advisors's CVKD Position: Q2 2026 in Review

Farther Finance Advisors held its Cadrenal Therapeutics (CVKD) position steady in Q2 2026 at 25 shares worth $84. The position accounts for ﹤0.01% of the portfolio, ranked #5808.

Farther Finance Advisors first reported a position in CVKD in Q4 2024 and has held it in 7 quarters since. The position peaked at $437 in Q1 2025. 20 funds tracked by Wall St. Rank hold CVKD as of Q2 2026.

  • Farther Finance Advisors held 25 shares of Cadrenal Therapeutics worth $84 as of Q2 2026.
  • Farther Finance Advisors left its Cadrenal Therapeutics share count unchanged in Q2 2026.
  • Cadrenal Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5808 holding.
  • Farther Finance Advisors first reported a position in Cadrenal Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Farther Finance Advisors's Cadrenal Therapeutics position peaked at $437 in Q1 2025.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.